NCT05508776View on ClinicalTrials.gov

A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions
Healthy VolunteersCardiac Repolarisation
Interventions
DRUG

LEO 152020

"Film-coated tablet~Route of administration: Orally~50 mg tablets"

DRUG

Moxifloxacin

"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"

DRUG

Placebo

"Film-coated tablet~Route of administration: Orally~No active ingredient"

Trial Locations (1)

LS2 9LH

LEO Investigational Site, Leeds

Sponsors

Lead Sponsor

JW Pharmaceutical

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

JW Pharmaceutical

INDUSTRY